DM
PTLA

Deerfield Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Deerfield Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-500,000
Closed -$16.3M – 128
2018
Q1 		$16.3M Buy
+500,000
New +$21.9M 0.57% 64

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

Deerfield Management's PTLA Position: Q2 2019 in Review

Deerfield Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2019, closing a stake of 2,617,543 shares — an estimated $90.8M sold.

Deerfield Management first reported a position in PTLA in Q2 2013 and held it in 23 quarters. The position peaked at $128M in Q3 2016. 201 funds tracked by Wall St. Rank hold PTLA as of Q2 2019.

  • Deerfield Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Deerfield Management sold 2,617,543 Portola Pharmaceuticals, Inc. shares in Q2 2019, an estimated $90.8M.
  • Deerfield Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 23 quarters.
  • Deerfield Management's Portola Pharmaceuticals, Inc. position peaked at $128M in Q3 2016.
  • 201 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2019.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.